Brian Posner Purchases 3,000 Shares of Dyne Therapeutics (NASDAQ:DYN) Stock

Dyne Therapeutics, Inc. (NASDAQ:DYN) Director Brian Posner acquired 3,000 shares of the company’s stock in a transaction that occurred on Friday, March 6th. The shares were acquired at an average cost of $15.06 per share, for a total transaction of $45,180.00. Following the acquisition, the director directly owned 11,500 shares of the company’s stock, valued at $173,190. This trade represents a 35.29% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link.

Dyne Therapeutics Price Performance

Dyne Therapeutics stock traded up $2.09 during midday trading on Tuesday, reaching $19.78. The company’s stock had a trading volume of 5,746,914 shares, compared to its average volume of 2,182,854. Dyne Therapeutics, Inc. has a fifty-two week low of $6.36 and a fifty-two week high of $25.00. The company has a debt-to-equity ratio of 0.15, a quick ratio of 22.25 and a current ratio of 22.25. The stock’s 50 day simple moving average is $17.01 and its 200 day simple moving average is $17.15. The firm has a market capitalization of $3.26 billion, a PE ratio of -5.59 and a beta of 1.34.

Dyne Therapeutics (NASDAQ:DYN) last issued its earnings results on Monday, March 2nd. The company reported ($0.76) EPS for the quarter, missing the consensus estimate of ($0.74) by ($0.02). On average, equities research analysts forecast that Dyne Therapeutics, Inc. will post -3.44 earnings per share for the current year.

Key Headlines Impacting Dyne Therapeutics

Here are the key news stories impacting Dyne Therapeutics this week:

• Positive Sentiment: Company reported new positive cardiopulmonary results from the DELIVER trial (z‑rostudirsen / DYNE‑251), which analysts and press framed as strengthening the DMD (Duchenne) therapeutic thesis — this data release is a direct clinical catalyst that can materially lift valuation if it supports later‑stage success. CALENDONIAN RECORD
• Positive Sentiment: Dyne announced initiation of the pivotal Phase III HARMONIA trial for DYNE‑101 (DM1), a clear regulatory/value inflection point that de‑risks the program and can drive re‑rating if enrollment and endpoints progress as expected. Yahoo News
• Positive Sentiment: Chardan Capital reaffirmed a “buy” rating and set a $38 price target, implying substantial upside vs. current levels — analyst support like this can attract momentum buyers and institutional interest. Benzinga
• Positive Sentiment: Insider buying: Director Brian S. Posner purchased 3,000 shares at about $15.06, increasing his stake ~35% — insider purchases are often interpreted as a bullish signal on management’s confidence. SEC Filing
• Positive Sentiment: Bull‑case commentary and analyst writeups highlight Dyne’s ~ $1.1B cash runway into mid‑2028 and view the DELIVER/HARMONIA catalysts as value drivers — financial runway reduces near‑term dilution risk and supports program execution. Seeking Alpha
• Neutral Sentiment: Reported short interest entries show zero shares and a 0.0 days‑to‑cover metric — either indicating minimal short pressure or data/reporting anomalies; this reduces the chance of a short‑squeeze dynamic but may reflect noisy data. (No article link)

Analyst Ratings Changes

DYN has been the subject of a number of research analyst reports. Wall Street Zen cut shares of Dyne Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday, December 28th. Oppenheimer upgraded Dyne Therapeutics from a “market perform” rating to an “outperform” rating and upped their price target for the stock from $11.00 to $40.00 in a report on Wednesday, December 10th. Morgan Stanley dropped their price objective on Dyne Therapeutics from $50.00 to $47.00 and set an “overweight” rating for the company in a research note on Monday, March 2nd. Tudor Pickering set a $23.00 price objective on Dyne Therapeutics in a report on Tuesday, December 9th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Dyne Therapeutics in a research report on Wednesday, January 21st. Three equities research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $36.13.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of DYN. Chung Wu Investment Group LLC acquired a new stake in Dyne Therapeutics during the 3rd quarter valued at $30,000. Strs Ohio acquired a new position in shares of Dyne Therapeutics in the fourth quarter worth $51,000. Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Dyne Therapeutics by 25.3% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,500 shares of the company’s stock worth $70,000 after acquiring an additional 1,109 shares during the last quarter. Aster Capital Management DIFC Ltd purchased a new stake in shares of Dyne Therapeutics in the fourth quarter valued at $84,000. Finally, Ameritas Investment Partners Inc. lifted its position in shares of Dyne Therapeutics by 11.1% in the second quarter. Ameritas Investment Partners Inc. now owns 9,582 shares of the company’s stock valued at $91,000 after acquiring an additional 955 shares in the last quarter. 96.68% of the stock is currently owned by institutional investors and hedge funds.

About Dyne Therapeutics

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.